Kini SP, DeLong LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147(10):1153–6.

Article  PubMed  Google Scholar 

Madigan LM, Fox LP. Where are we now with inpatient consultative dermatology?: Assessing the value and evolution of this subspecialty over the past decade. J Am Acad Dermatol. 2019;80(6):1804–8.

Article  PubMed  Google Scholar 

Joseph J, Truong K, Smith A, Fernandez-Penas P. Dermatology inpatient consultations in a tertiary hospital–a retrospective analysis. Int J Dermatol. 2022;61(1):48–53.

Article  PubMed  Google Scholar 

Roh YS, Choi J, Sutaria N, Kwatra SG. Itch: Epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022;86(1):1–14.

Article  PubMed  Google Scholar 

Lipman ZM, Ingrasci G, Yosipovitch G. Approach to the patient with chronic pruritus. Med Clin. 2021;105(4):699–721.

Google Scholar 

Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502–7.

Article  PubMed  Google Scholar 

Lay C-J, Wang C-L, Chuang H-Y, Chen Y-L, Chen H-L, Tsai S-J, et al. Risk factors for delayed diagnosis of scabies in hospitalized patients from long-term care facilities. J  Clin Med Res. 2011:72–7.

• Tso S, Satchwell F, Moiz H, Hari T, Dhariwal S, Barlow R, et al. Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation and pathogenesis. Clin Exp Dermatol. 2021;46(6):1001–10. Provides a comprehensive review of causes and pathophysiology of erythroderma.

Sarkar R, Sharma RC, Koranne RV, Sardana K. Erythroderma in children: a clinico-etiological study. J Dermatol. 1999;26(8):507–11.

Article  CAS  PubMed  Google Scholar 

Askin O, Altunkalem RN, Uzuncakmak TK, Toplu FŞ, Engin B. Erythroderma: a clinicopathological study of 47 cases from 2018 to 2020. Dermatol Ther. 2020;33(6): e14342.

Article  PubMed  Google Scholar 

Li J, Zheng H-Y. Erythroderma: a clinical and prognostic study. Dermatology. 2012;225(2):154–62.

Article  PubMed  Google Scholar 

•• Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, et al. Efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis: a post hoc analysis of 6 randomized clinical trials. JAMA Dermatol. 2023. Post-hoc anaylsis showing that dupilumab effectively reduces percentage of body surface area affected, EASI score, and peak pruritus NRS score in patients with erythrodermic AD.

Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas M. A practical approach to the diagnosis and treatment of adult erythroderma. Actas Dermo-Sifiliográficas (English Edition). 2018;109(9):777–90.

Article  CAS  Google Scholar 

Labib A, Does AV, Korbutov J, Yosipovitch G. Silicone barrier cream in treatment of atopic dermatitis: a literature review. Dermatol Ther. 2022:e15884.

• Chung BY, Kim HB, Jung MJ, Kang SY, Kwak I-S, Park CW, et al. Post-burn pruritus. Int J Mol Sci. 2020;21(11):3880. Provides a comprehensive review of post-burn pruritus.

Fowler E, Yosipovitch G. Post-burn pruritus and its management—current and new avenues for treatment. Curr Trauma Rep. 2019;5(2):90–8.

Article  Google Scholar 

Goutos I, Clarke M, Upson C, Richardson PM, Ghosh SJ. Review of therapeutic agents for burns pruritus and protocols for management in adult and paediatric patients using the GRADE classification. Ind J Plastic Surg. 2010;43(S 01):S51-S62.

Ahuja RB, Gupta GK. A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. Burns. 2013;39(1):24–9.

Article  PubMed  Google Scholar 

Storan ER, McEvoy MT, Wetter DA, el-Azhary RA, Hand JL, Davis DM, et al. Pediatric hospital dermatology: experience with inpatient and consult services at the Mayo Clinic. Pediatr Dermatol. 2013;30(4):433–7.

Cathcart S, Theos A. Inpatient management of atopic dermatitis. Dermatol Ther. 2011;24(2):249–55.

Article  PubMed  Google Scholar 

• Narla S, Silverberg JI. Management of atopic dermatitis in the inpatient setting. Curr Dermatol Rep. 2021;10(3):77–88. Provides an updated review for the management of AD in the inpatient setting and highlights the benefit of a multidisciplinary approach.

Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51(3):263–92.

Article  CAS  PubMed  Google Scholar 

Prodanovich S, Kirsner RS, Taylor JR. Treatment of patients hospitalized for psoriasis. Dermatol Clin. 2000;18(3):425–35.

Article  CAS  PubMed  Google Scholar 

Shao S, Wang G, Maverakis E, Gudjonsson JE. Targeted treatment for erythrodermic psoriasis: rationale and recent advances. Drugs. 2020;80(6):525–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Q, Jin L, Hu K, Tan M, Lu Y, Zhao Y, et al. The length of stay and inpatient burden in inpatients with different psoriasis subtypes. Int J Med Sci. 2022;19(10):1519–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyachi H, Konishi T, Kumazawa R, Matsui H, Shimizu S, Fushimi K, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266–74.

Article  PubMed  Google Scholar 

Hadeler E, Mosca M, Hong J, Brownstone N, Liao W, Bhutani T, et al. Inpatient management of psoriasis: a current perspective and update for clinicians. Curr Dermatol Rep. 2021:1–17.

Kahremany S, Hofmann L, Harari M, Gruzman A, Cohen G. Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives. Pharmacol Rep. 2021;73(2):443–53.

Article  PubMed  Google Scholar 

Vensel E, Hilley T, Trent J, Taylor JR, Kirsner RS, Kerdel FA, et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol. 2000;43(5):858–60.

Article  CAS  PubMed  Google Scholar 

Giannotti B, Carli P, Veller-Fornasa C, Cancian G, Fadel A, Amerio P, et al. Management of erythrodermic psoriasis with low-dose cyclosporin. Dermatology. 1993;187(SUPPL. 1):30–7.

Google Scholar 

Yosipovitch G, Soung J, Weiss J, Muscianisi E, Meng X, Gilloteau I, et al. Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. Acta Derm Venereol. 2019;99(9):820–1.

Article  CAS  PubMed  Google Scholar 

Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156–61.

Article  CAS  PubMed  Google Scholar 

•• Maçães CO, Lé AM, Torres T. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors. J Dermatol Treat. 2022;33(7):2911–8. Highlights clinical trials that evaluate the efficacy of IL-36 inhibitors in treating psoriasis flares.

Baigrie D, Nookala V. Bullous Pemphigoid. StatPearls [Internet]: StatPearls Publishing; 2021.

Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):53–62.

Article  CAS  PubMed  Google Scholar 

Ren Z, Hsu D, Brieva J, Silverberg N, Langan S, Silverberg J. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the USA. Br J Dermatol. 2017;176(1):87–99.

Article  CAS  PubMed  Google Scholar 

Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513–28.

Article  PubMed  Google Scholar 

•• Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52. In this case series, 11 out of 13 bullous pemphigoid patients reported resolution of their itch while using dupilumab.

London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148(11):1241–3.

Article  CAS  PubMed  Google Scholar 

Kenneth KY, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–74.

Article  Google Scholar 

Lipozenčić J, Ljubojevic S, Bukvić-Mokos Z. Pemphigoid gestationis. Clin Dermatol. 2012;30(1):51–5.

Article  PubMed  Google Scholar 

Palmsten K, Bandoli G, Watkins J, Vazquez-Benitez G, Gilmer TP, Chambers CD. Oral corticosteroids and risk of preterm birth in the California Medicaid program. The J Allergy Clin Immunol: In Practice. 2021;9(1):375–84. e5.

Palmsten K, Bandoli G, Vazquez-Benitez G, Xi M, Johnson DL, Xu R, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology. 2020;59(6):1262–71.

Article  CAS  PubMed  Google Scholar 

Riquelme-Mc Loughlin C, Mascaró J Jr. Treatment of pemphigoid gestationis with dupilumab. Clin Exp Dermatol. 2021;46(8):1578–9.

Article  CAS  PubMed  Google Scholar 

Shakuntulla F, Chiarella SE. Safety of biologics for atopic diseases during pregnancy. J Allergy Clin Immunol: In Practice. 2022;10(12):3149–55.

Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760–8.

Article  PubMed  PubMed Central  Google Scholar 

• Ottevanger R, van Beugen S, Evers AW, Willemze R, Vermeer MH, Quint KD. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 2022;9:57–64. This cross-sectional cohort study showed that itch correlates significantly with a more impaired quality of life in patients with CTCL.

Nattkemper LA, Martinez-Escala M-E, Gelman AB, Singer EM, Rook AH, Guitart J, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm-Venereol. 2016;96(7).

Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowe B, Yosipovitch G. Malignancy-associated pruritus. Eur J Pain. 2016;20(1):19–23.

Article  CAS  PubMed  Google Scholar 

Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73(5):843–8.

Article  PubMed  Google Scholar 

Nusbaum KB, Walker TD, Himed S, Trinidad JC, Spaccarelli N, Chung C, et al. Patient care outcomes in hospitalized patients with acute generalized exanthematous pustulosis: a cross-sectional database study. Am J Clin Dermatol. 2022:1–6.

Hadavand MA, Kaffenberger B, Cartron AM, Trinidad JC. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2020.

Munshi M, Junge A, Gadaldi K, Yawalkar N, Heidemeyer K. Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine. JAAD case reports. 2020;6(7):634–6.

Article